|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SIGLEC10 |
Gene summary for SIGLEC10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SIGLEC10 | Gene ID | 89790 |
| Gene name | sialic acid binding Ig like lectin 10 | |
| Gene Alias | PRO940 | |
| Cytomap | 19q13.41 | |
| Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | B7ZL06 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 89790 | SIGLEC10 | HCC1 | Human | Liver | HCC | 3.16e-16 | 1.72e+00 | 0.5336 |
| 89790 | SIGLEC10 | HCC2 | Human | Liver | HCC | 1.00e-24 | 1.90e+00 | 0.5341 |
| 89790 | SIGLEC10 | HCC5 | Human | Liver | HCC | 2.49e-20 | 1.31e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190303421 | Liver | HCC | regulation of response to wounding | 94/7958 | 167/18723 | 2.19e-04 | 1.66e-03 | 94 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SIGLEC10 | SNV | Missense_Mutation | c.1252N>C | p.Glu418Gln | p.E418Q | Q96LC7 | protein_coding | deleterious(0.03) | possibly_damaging(0.842) | TCGA-91-6840-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SIGLEC10 | SNV | Missense_Mutation | novel | c.401N>A | p.Gly134Glu | p.G134E | Q96LC7 | protein_coding | tolerated(0.99) | benign(0.103) | TCGA-91-8499-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIGLEC10 | SNV | Missense_Mutation | c.1312N>A | p.Leu438Ile | p.L438I | Q96LC7 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| SIGLEC10 | SNV | Missense_Mutation | c.1111C>A | p.Leu371Met | p.L371M | Q96LC7 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-97-8174-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | vinorelbine | SD | |
| SIGLEC10 | SNV | Missense_Mutation | novel | c.901T>C | p.Trp301Arg | p.W301R | Q96LC7 | protein_coding | tolerated(0.5) | benign(0.021) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SIGLEC10 | SNV | Missense_Mutation | novel | c.1898N>T | p.Ser633Leu | p.S633L | Q96LC7 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-22-1000-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SIGLEC10 | SNV | Missense_Mutation | c.193N>T | p.Thr65Ser | p.T65S | Q96LC7 | protein_coding | tolerated(0.1) | benign(0.038) | TCGA-22-5489-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | taxotere | PD | |
| SIGLEC10 | SNV | Missense_Mutation | c.1108N>C | p.Val370Leu | p.V370L | Q96LC7 | protein_coding | deleterious(0) | possibly_damaging(0.771) | TCGA-33-4533-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SIGLEC10 | SNV | Missense_Mutation | rs755021240 | c.1757C>T | p.Pro586Leu | p.P586L | Q96LC7 | protein_coding | deleterious(0.02) | benign(0.065) | TCGA-33-4583-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SIGLEC10 | SNV | Missense_Mutation | c.1718T>G | p.Ile573Ser | p.I573S | Q96LC7 | protein_coding | tolerated(0.06) | benign(0.017) | TCGA-39-5022-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |